Introduction
GASTROINTESTINAL STROMAL TUMOR (GIST), TUMOR GROWTH, GASTROINTESTINAL STROMAL TUMOR, GIST
Gastrointestinal stromal tumor (GIST) is the most common gastrointestinal stromal tumor.Anlotinib is a multi-target tyrosine kinase inhibitor, which can inhibit angiogenesis and tumor growth. It can effectively inhibit KIT, VEGFR, PDGFR, FGFR, and other targets. Meanwhile, it showed certain anti-tumor activity in the treatment of GIST with KIT D816H, V560G, V654A, and PDGFRA D842V mutation.In our study, we tested the inhibitory effect of anlotinib in GIST cell lines with different gene mutations, and conducted a prospective multicenter clinical trial to evaluate the efficacy and safety of second-line treatment of GIST with anlotinib, and compared the efficacy with patients receiving second-line treatment with sunitinib in the same period. The clinical trial registration number is NCT04106024.